SSA
FLNA

Schonfeld Strategic Advisors’s Filana Therapeutics FLNA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-68,215
Closed -$1.65M – 2454
2023
Q1 		$1.65M Buy
+68,215
New +$1.89M 0.02% 752
2022
Q4 		– Sell
-12,000
Closed -$502K – 2957
2022
Q3 		$502K Buy
+12,000
New +$324K ﹤0.01% 1747

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Schonfeld Strategic Advisors's FLNA Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of Filana Therapeutics (FLNA) in Q2 2023, closing a stake of 68,215 shares — an estimated $1.65M sold.

Schonfeld Strategic Advisors first reported a position in FLNA in Q3 2022 and held it in 2 quarters. The position peaked at $1.65M in Q1 2023. 152 funds tracked by Wall St. Rank hold FLNA as of Q2 2023.

  • Schonfeld Strategic Advisors reported no remaining Filana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 68,215 Filana Therapeutics shares in Q2 2023, an estimated $1.65M.
  • Schonfeld Strategic Advisors first reported a position in Filana Therapeutics in Q3 2022 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Filana Therapeutics position peaked at $1.65M in Q1 2023.
  • 152 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.